The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Fact checked by Nick Blackmer More people with type 1 diabetes are using GLP-1s like Ozempic and Zepbound, a new study ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less ...